Диссертация (1154906), страница 16
Текст из файла (страница 16)
vol.53. – p.1013–1020.96. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state andcirculating erythropoietin in persons with and without anemia. // Am J Med.– 2005. - vol.118. – p.1288.97. Macdougall IC, Cooper AC. Erythropoietin resistance: the role ofinflammation and pro-inflammatory cytokines. // Nephrol Dial Transplant. –2002. - vol.17. – p.39–43.98. Deicher R, Ho¨ rl WH. Hepcidin: a molecular link between inflammationand anaemia. // Dial Transplant. – 2004. - vol.19. – p.521–524.99. De´ tivaud l, Nemeth E, Boudjema K, et al.
Hepcidin levels in humans arecorrelated with hepatic iron stores, hemoglobin levels, and hepatic function.// Blood. – 2005. - vol. 106. – p.746–748.103100. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parametersand mortality in patients with chronic heart failure. // Circulation. – 2000. vol. 102.
– p.3060– 3067.101. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia inpatients with chronic kidney disease. // Curr Med Res Opin. – 2004. vol.20. – p.1501-1510.102. Kazory A, Ross EA. Anemia: the point of convergence or divergence forkidney disease and heart failure? // J Am Coll Cardiol. - 2009. - vol. 53. –p.639–647.103. Witte KKA, Desilva R, Chattopadhyay S, et al. Are hematinicdeficiencies the cause of anemia in chronic heart failure? // Am Heart J2004. - vol. 147. – p.924–930.104.
Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging roleof the gut in chronic heart failure. // Curr Opin Clin Nutr Metab Care. –2008. - vol.11. – p.632– 639.105. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin productionand defective iron supply for erythropoiesis as major causes of anaemia inpatients with chronic heart failure. // Eur Heart J.
– 2005. - vol. 26. –p.2232–2237.106. Ishani A, Weinhandl E, Zhao Z, et al. Angiotensin-converting enzymeinhibitors as a risk factor for the development of anemia, and the impact ofincident anemia on mortality in patients with left ventricular dysfunction. // JAm Coll Cardiol. – 2005. - vol. 45. – p.391–399.107. Van der Meer P, Lipsic E, Westenbrink BD, et al.
Levels ofhematopoiesisinhibitorN-acetyl-seryl-aspartyl-lysyl-prolinepartiallyexplain the occurrence of anemia in heart failure. // Circulation. – 2005. vol. 112. – p.1743–1747.104108. Westenbrink BD, de Boer RA, Voors AA, et al. Anemia in chronic heartfailure: etiology and treatment options. // Curr Opin Cardiol.
– 2008. - vol.23. – p.141–147.109. Adlbrecht C, Kommata S, Hu¨ lsmann M, et al. Chronic heart failureleads to an expanded plasma volume and pseudoanaemia, but does not leadto a reduction in the body’s red cell volume // Eur Heart J. – 2008. - vol.29.– p.2343–2350. 106. Iverson PO, Woldbaek PR, Tonnessen T, ChristensenG. Decreased hematopoiesis in bone marrow of mice with congestive heartfailure. Am J Physiol Regul Integr Comp Physiol 2002;282:R166–R172.110. Bolger AP, Haehling S, Doehner W, Poole-Wilson PA, Coats AJ, AnkerSD.
Anemia and inflammation in chronic heart failure. // J Card Fail. –2003. - Vol. 9. – p.33.111. Van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, vanVeldhuisen DJ. Prognostic value of plasma erythropoietin on mortality inpatients with chronic heart failure. // J Am Coll Cardiol. - 2004. - vol. 44. –p.63–67.112. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia inpatients with advanced heart failure. // J Am Coll Cardiol. – 2006.
– vol. 48.– p.2485-2489.113. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneouserythropoietin and intravenous iron for the treatment of the anemia ofsevere, resistant congestive heart failure improves cardiac and renal functionand functional cardiac class, and markedly reduces hospitalizations. // J AmColl Cardiol. – 2000. - vol. 35(7). – p.1737–1744.114. Кобалава Ж. Д. Кардиоренальный синдром. / Кобалава Ж.
Д.,Моисеев В.С. // Клин. фармакология и терапия. – 2002. №3. – С. 16‒18.105115. Мухин Н.А. Кардиоренальные соотношения и риск сердечнососудистых заболеваний. / Мухин Н.А., Моисеев В.С. // ВестникРАМН. – 2003. - №11. – С. 50–55.116. Кардиоренальные синдромы: классификация, патофизиологическиемеханизмы, принципы диагностики. / Кобалава Ж.Д., ВиллевальдеС.В., Ефремовцева М.А, Тюхменев Е.А., Клименко А.С.
// Врач. – 2011.- №5. – С. 2‒6.117. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenalsyndrome. // J Am Coll Cardiol. – 2008. vol.52(19). – p.1527–1539.118. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining thedefinition of a complex symbiosis gone wrong. // Intensive Care Med. –2008. - vol.34(5).
– p.957–962.119. Ronco C, House AA, Haapio M. Cardiorenal and renocardiac syndromes:the need for a comprehensive classification and consensus. // Nat Clin PractNephrol. – 2008. - vol. 4(6). – p.310–311.120. Damman K, Navis G, Smilde TDJ, et al. Decreased cardiac output,venous congestion and the association with renal impairment in patientswith cardiac dysfunction // Eur J Heart Failure. – 2007. - vol.9(9).
– p. 872878.121. KannelWB.Epidemiologyandpreventionofcardiacfailure:Framingham Study insights. // Eur Heart J. – 1987. - vol.8Suppl. – p.F23–F26.122. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renalinsufficiency and heart failure: prognostic and therapeutic implications froma prospective cohort study.
// Circulation. – 2004. - vol.109(8). – p.1004–1009.106123. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogenlevel as a predictor of mortality in patients admitted for decompensated heartfailure. // Am J Med. – 2004. - vol.116(7). – p.466–473.124. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of bloodurea nitrogen in patients hospitalized with worsening heart failure: insightsfrom the Acute and Chronic Therapeutic Impact of a VasopressinAntagonist in Chronic Heart Failure (ACTIV in CHF) study. // J Card Fail. –2007. - vol.13(5). – p.360–364.125. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. Theprognostic implications of renal insufficiency in asymptomatic andsymptomatic patients with left ventricular systolic dysfunction. // J Am CollCardiol.
– 2000. - vol.35(3). – p.681–689.126. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance ofdifferent definitions of worsening renal function in congestive heart failure.// J Card Fail. – 2002. - vol.8(3). – p.136–141.122.Silverberg DS, WexlerD, Blum M, et al. The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renalfailure by subcutaneous erythropoietin and intravenous iron.
// Nephrol DialTransplant. – 2003. - vol.18(1). – p.141–146.127. Vaisman N, Silverberg DS, Wexler D, et al. Correction of anemia inpatients with congestive heart failure increases resting energy expenditure. //Clin Nutr. – 2004. - vol.23(3). – p.355–361.128. Silverberg DS, Wexler D, Blum M, et al. Effects of treatment withepoetin beta on outcomes in patients with anaemia and chronic heart failure.// Kidney Blood Press Res. – 2005. - vol.28(1). – p.41–47.129. Zilberman M, Silverberg DS, Bits I, et al. Improvement of anemia witherythropoietin and intravenous iron reduces sleep-related breathing disorders107and improves daytime sleepiness in anemic patients with congestive heartfailure. // Am Heart J.
– 2007. - vol.154(5). – p.870–876.130. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy ofcongestive heart failure and associated chronic renal failure withmedications and correction of anemia stops or slows the progression of bothdiseases. // Perit Dial Int.
– 2001. - vol.21 Suppl 3. – p.S236–S240.131. Qian C, Wei B, Ding J, Wu H, Wang Y. The Efficacy and Safety of IronSupplementation in Patients With Heart Failure and Iron Deficiency: ASystematic Review and Meta-analysis. // Can J Cardiol. – 2016. - vol.32(2).– p.151-9.132. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S,Doehner W, et al. Effects of intravenous iron therapy in iron-deficientpatients with systolic heart failure: a meta-analysis of randomized controlledtrials.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
